Clinical Trial Update: Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on the 13-valent pneumococcal conjugate vaccine in healthy Japanese infants; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Vaccines, Pneumococcal Conjugate Vaccine | Phase 3 | Status: COMPLETED | Results posted: 2012-08-08